Diffusion Pharmaceuticals Stock Price, News & Analysis

Diffusion Pharmaceuticals Inc. (DFFN) is a clinical-stage biopharmaceutical company dedicated to enhancing the efficacy of standard-of-care therapies for life-threatening, treatment-resistant solid cancerous tumors. The company's flagship product, Trans Sodium Crocetinate (TSC), focuses on re-oxygenating the hypoxic (oxygen-deprived) microenvironment of tumors, thereby improving the effectiveness of conventional treatments like radiation and chemotherapy.

TSC has earned the Orphan Drug Designation from the FDA for its application in several cancers where tumor hypoxia undermines current therapeutic strategies. This innovative drug targets the hypoxic areas within tumors, making the cancer cells more susceptible to established treatments without adding harmful side effects.

Diffusion Pharmaceuticals is preparing to embark on a pivotal Phase 3 trial in glioblastoma (GBM), a particularly aggressive form of brain cancer, by 2016. Additionally, the company has plans for Phase 2/3 trials in pancreatic cancer and brain metastases, reflecting the broad applicability of TSC's unique mechanism of action across various tumor types.

Financially, Diffusion Pharmaceuticals is strategically positioning itself with strong partnerships and an innovative pipeline, aiming to make significant strides in cancer treatment. The company's ongoing projects and achievements underscore its commitment to revolutionizing oncological care by leveraging TSC's potential to safely and effectively re-oxygenate diverse tumor tissues.